Advertisement

Topics

Du Pont-Sankyo Pharmaceuticals Company Limited Company Profile

06:30 EST 25th November 2017 | BioPortfolio

Diagnostics

Location

Daini Kowa Building 11-39 Akasaka 1-chome Minato-ku
Tokyo
Tokyo
107
Japan

Contact

Phone: 81 3 3585 4050
Fax: 81 3 3587 0336


News Articles [1035 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo, Boston Pharmaceuticals sign deal for selective RET inhibitor for solid tumors

Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (F...

Daiichi Sankyo Q1 Profit Down; Sees Higher Profit, Lower Sales In FY

TOKYO (dpa-AFX) - Japanese pharmaceuticals company Daiichi Sankyo Co. Ltd. (DSKYF.PK) reported Monday that its first-quarter profit attributable to owners of the company declined 4.7 percent to 29...

Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an optio...

Daiichi Sankyo inks Glycotope ADC deal

Daiichi Sankyo Company has signed an option agreement to develop Glycotopeâs antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.

Daiichi Sankyo and MD Anderson Collaborate to Accelerate Development of Acute Myeloid Leukemia Therapies

HOUSTON and TOKYO and BASKING RIDGE, N.J., Sept. 14, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today a...

Daiichi Sankyo announces support from Japan AMRD's CiCLE programme for genetic vaccine platform

Daiichi Sankyo, Company Limited announced that its development of the genetic vaccine platform utilizing in─house developed new nucleic acid delivery technology has been adopted for support under th...

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in ...

Zymeworks:David Poon, Ph.D.Executive Director, External R&D and Alliances(604) 678-1388bd@zymeworks.comorInvestor Inquiries:David MatousekSenior Manager, Investor Relations & ...

Drugs and Medications [1579 Associated Drugs and Medications listed on BioPortfolio]

Ranitidine [WOCKHARDT LIMITED]

Ranitidine [WOCKHARDT LIMITED]

Drug Facts

Famotidine [WOCKHARDT LIMITED]

Famotidine Tablets, USP 20 mg

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Simethicone [SPIRIT PHARMACEUTICALS,LLC]

SIMETHICONE, CAPSULES USP 125MG

PubMed Articles [141 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Editorial: In Good Company.

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Clinical Trials [275 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Companies [2780 Associated Companies listed on BioPortfolio]

Du Pont-Sankyo Pharmaceuticals Company Limited

Diagnostics

Sankyo Co., Ltd.

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eager...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

More Information about "Du Pont-Sankyo Pharmaceuticals Company Limited" on BioPortfolio

We have published hundreds of Du Pont-Sankyo Pharmaceuticals Company Limited news stories on BioPortfolio along with dozens of Du Pont-Sankyo Pharmaceuticals Company Limited Clinical Trials and PubMed Articles about Du Pont-Sankyo Pharmaceuticals Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Du Pont-Sankyo Pharmaceuticals Company Limited Companies in our database. You can also find out about relevant Du Pont-Sankyo Pharmaceuticals Company Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record